Literature DB >> 15996062

Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis.

Frederick Wolfe1, Kaleb Michaud, Theodore Pincus.   

Abstract

OBJECTIVE: Key outcomes in rheumatoid arthritis (RA) are evaluated with multi-item ratings scales such as the Health Assessment Questionnaire (HAQ) and visual analog scales (VAS) such as pain and patient and physician global. As VAS scales are easy to use and particularly effective in research and patient care, we studied the characteristics, association, and psychometric properties of a VAS function scale (VAS-F) to determine if it could be used in RA studies and clinical practice.
METHODS: A total of 394 patients with RA completed the HAQ, the HAQ-II, and a VAS functional scale. In addition, they completed standard assessments of pain, global, fatigue, sleep problems, joint count, and the Medical Outcome Study Short-Form 36 (SF-36) physical component summary score (PCS) and vitality and total pain scores.
RESULTS: The HAQ-II was correlated with VAS-F at 0.76, but distributional characteristics of the HAQ and VAS-F differed, as the VAS-F scale results contained more higher scores as well as more lower scores compared with the HAQ-II and HAQ. Kendall's tau concordance analyses indicated that VAS scales were more concordant with other VAS than with non-VAS scales. Concordance of VAS-F was greatest with VAS global and was similar overall with VAS pain, sleep disturbance, fatigue, and quality of life. By contrast, the PCS, a multi-item scale, was more concordant with HAQ-II and HAQ. There was little to no difference between the VAS-F and the 2 HAQ with regard to concordance with the multi-item joint count, SF-36 vitality, and SF-36 total pain.
CONCLUSION: The distribution differences between HAQ and HAQ-II and the VAS-F suggest that patients do not see minor limitations as problematic, but rate major limitations as being particularly limiting and worthy of high ratings. A VAS functional scale represents a patient-weighted functional assessment in which additional interpretation is given to the meaning of the limitations by the patient. VAS-F scales may be suitable for use in the clinic and in research. However, studies to assess sensitivity to change are required to determine the appropriate role of this scale.

Entities:  

Mesh:

Year:  2005        PMID: 15996062

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  [Higher prevalence of depressive and anxiety symptoms in early arthritis patients in comparison to the normal population].

Authors:  D Freier; M Englbrecht; V Höhne-Zimmer; J Detert; G-R Burmester
Journal:  Z Rheumatol       Date:  2019-11       Impact factor: 1.372

2.  Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures.

Authors:  Tessa Sanderson; John Kirwan; Celia Almeida; Marianne Morris; Robert Noddings; Sarah Hewlett
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

3.  Fatigue: a frequent and biologically based phenomenon in newly diagnosed celiac disease.

Authors:  Berit Mære Skjellerudsveen; Roald Omdal; Anne Kristine Hetta; Jan Terje Kvaløy; Lars Aabakken; Inger Marie Skoie; Tore Grimstad
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

4.  Perception of surgical complications among patients, nurses and physicians: a prospective cross-sectional survey.

Authors:  Milo A Puhan; Pierre-Alain Clavien; Ksenija Slankamenac; Rolf Graf
Journal:  Patient Saf Surg       Date:  2011-11-22

5.  Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis.

Authors:  Rebecca Heijke; Mathilda Björk; Ingrid Thyberg; Alf Kastbom; Laura McDonald; Christopher Sjöwall
Journal:  Clin Rheumatol       Date:  2021-11-27       Impact factor: 3.650

6.  Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Authors:  Proton Rahman; Philip J Mease; Philip S Helliwell; Atul Deodhar; Laure Gossec; Arthur Kavanaugh; Alexa P Kollmeier; Elizabeth C Hsia; Bei Zhou; Xiwu Lin; May Shawi; Chetan S Karyekar; Chenglong Han
Journal:  Arthritis Res Ther       Date:  2021-07-14       Impact factor: 5.156

7.  Effects of dietary supplementation with a standardized aqueous extract of Terminalia chebula fruit (AyuFlex®) on joint mobility, comfort, and functional capacity in healthy overweight subjects: a randomized placebo-controlled clinical trial.

Authors:  H L Lopez; S M Habowski; J E Sandrock; B Raub; A Kedia; E J Bruno; T N Ziegenfuss
Journal:  BMC Complement Altern Med       Date:  2017-10-02       Impact factor: 3.659

Review 8.  Fatigue - an underestimated symptom in psoriatic arthritis.

Authors:  Magdalena Krajewska-Włodarczyk; Agnieszka Owczarczyk-Saczonek; Waldemar Placek
Journal:  Reumatologia       Date:  2017-07-18

9.  Prevalence and severity of fatigue in psoriasis and psoriatic arthritis.

Authors:  Magdalena Krajewska-Włodarczyk; Agnieszka Owczarczyk-Saczonek; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2020-03-09       Impact factor: 1.837

Review 10.  Latin American Genes: The Great Forgotten in Rheumatoid Arthritis.

Authors:  Roberto Díaz-Peña; Luis A Quiñones; Patricia Castro-Santos; Josefina Durán; Alejandro Lucia
Journal:  J Pers Med       Date:  2020-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.